113 related articles for article (PubMed ID: 9632001)
1. Administration of DAB389IL-2 to patients with recalcitrant psoriasis: a double-blind, phase II multicenter trial.
Bagel J; Garland WT; Breneman D; Holick M; Littlejohn TW; Crosby D; Faust H; Fivenson D; Nichols J
J Am Acad Dermatol; 1998 Jun; 38(6 Pt 1):938-44. PubMed ID: 9632001
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides.
Saleh MN; LeMaistre CF; Kuzel TM; Foss F; Platanias LC; Schwartz G; Ratain M; Rook A; Freytes CO; Craig F; Reuben J; Sams MW; Nichols JC
J Am Acad Dermatol; 1998 Jul; 39(1):63-73. PubMed ID: 9674399
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2.
LeMaistre CF; Saleh MN; Kuzel TM; Foss F; Platanias LC; Schwartz G; Ratain M; Rook A; Freytes CO; Craig F; Reuben J; Nichols JC
Blood; 1998 Jan; 91(2):399-405. PubMed ID: 9427692
[TBL] [Abstract][Full Text] [Related]
4. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
Spuls PI; Hooft L
Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
[TBL] [Abstract][Full Text] [Related]
5. A multicenter dose-escalation trial with denileukin diftitox (ONTAK, DAB(389)IL-2) in patients with severe psoriasis.
Martin A; Gutierrez E; Muglia J; McDonald CJ; Guzzo C; Gottlieb A; Pappert A; Garland WT; Bagel J; Bacha P
J Am Acad Dermatol; 2001 Dec; 45(6):871-81. PubMed ID: 11712032
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial.
Kimball AB; Bensimon AG; Guerin A; Yu AP; Wu EQ; Okun MM; Bao Y; Gupta SR; Mulani PM
Am J Clin Dermatol; 2011 Feb; 12(1):51-62. PubMed ID: 21110526
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
Tyring S; Gordon KB; Poulin Y; Langley RG; Gottlieb AB; Dunn M; Jahreis A
Arch Dermatol; 2007 Jun; 143(6):719-26. PubMed ID: 17576937
[TBL] [Abstract][Full Text] [Related]
8. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.
Lebwohl M; Christophers E; Langley R; Ortonne JP; Roberts J; Griffiths CE;
Arch Dermatol; 2003 Jun; 139(6):719-27. PubMed ID: 12810502
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis.
Krueger GG; Papp KA; Stough DB; Loven KH; Gulliver WP; Ellis CN;
J Am Acad Dermatol; 2002 Dec; 47(6):821-33. PubMed ID: 12451365
[TBL] [Abstract][Full Text] [Related]
10. The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody.
Papp K; Bissonnette R; Krueger JG; Carey W; Gratton D; Gulliver WP; Lui H; Lynde CW; Magee A; Minier D; Ouellet JP; Patel P; Shapiro J; Shear NH; Kramer S; Walicke P; Bauer R; Dedrick RL; Kim SS; White M; Garovoy MR
J Am Acad Dermatol; 2001 Nov; 45(5):665-74. PubMed ID: 11606914
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).
Papp KA; Langley RG; Lebwohl M; Krueger GG; Szapary P; Yeilding N; Guzzo C; Hsu MC; Wang Y; Li S; Dooley LT; Reich K;
Lancet; 2008 May; 371(9625):1675-84. PubMed ID: 18486740
[TBL] [Abstract][Full Text] [Related]
12. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis.
Gottlieb SL; Gilleaudeau P; Johnson R; Estes L; Woodworth TG; Gottlieb AB; Krueger JG
Nat Med; 1995 May; 1(5):442-7. PubMed ID: 7585092
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
Menter A; Gordon K; Carey W; Hamilton T; Glazer S; Caro I; Li N; Gulliver W
Arch Dermatol; 2005 Jan; 141(1):31-8. PubMed ID: 15655139
[TBL] [Abstract][Full Text] [Related]
14. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.
Krueger GG; Langley RG; Finlay AY; Griffiths CE; Woolley JM; Lalla D; Jahreis A
Br J Dermatol; 2005 Dec; 153(6):1192-9. PubMed ID: 16307657
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial.
Igarashi A; Kato T; Kato M; Song M; Nakagawa H;
J Dermatol; 2012 Mar; 39(3):242-52. PubMed ID: 21955098
[TBL] [Abstract][Full Text] [Related]
16. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
Bachelez H; van de Kerkhof PC; Strohal R; Kubanov A; Valenzuela F; Lee JH; Yakusevich V; Chimenti S; Papacharalambous J; Proulx J; Gupta P; Tan H; Tawadrous M; Valdez H; Wolk R;
Lancet; 2015 Aug; 386(9993):552-61. PubMed ID: 26051365
[TBL] [Abstract][Full Text] [Related]
17. Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis.
Menter A; Kosinski M; Bresnahan BW; Papp KA; Ware JE
J Drugs Dermatol; 2004; 3(1):27-38. PubMed ID: 14964744
[TBL] [Abstract][Full Text] [Related]
18. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.
Gordon KB; Papp KA; Hamilton TK; Walicke PA; Dummer W; Li N; Bresnahan BW; Menter A;
JAMA; 2003 Dec; 290(23):3073-80. PubMed ID: 14679270
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).
Leonardi CL; Kimball AB; Papp KA; Yeilding N; Guzzo C; Wang Y; Li S; Dooley LT; Gordon KB;
Lancet; 2008 May; 371(9625):1665-74. PubMed ID: 18486739
[TBL] [Abstract][Full Text] [Related]
20. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.
Papp KA; Leonardi C; Menter A; Ortonne JP; Krueger JG; Kricorian G; Aras G; Li J; Russell CB; Thompson EH; Baumgartner S
N Engl J Med; 2012 Mar; 366(13):1181-9. PubMed ID: 22455412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
